AstraZeneca PLC Director/PDMR Shareholding (6358K)
06 Maio 2022 - 12:00PM
UK Regulatory
TIDMAZN
RNS Number : 6358K
AstraZeneca PLC
06 May 2022
6 May 2022 16:00 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announces that, on 5 May 2022, it
was notified of a transaction in the Company's American Depositary
Shares (ADSs) by Andreas Rummelt, Non-Executive Director, as set
out below. Two ADSs are equivalent to one of the Company's ordinary
shares of $0.25 each.
PDMR Position Nature of the Quantity Price
transaction
Andreas Rummelt Non-Executive Director Sale of ADSs 15,170 US$65.23
----------------------- -------------- --------- ---------
Further details are set out in the attached notification, made
in accordance with the requirements of the EU Market Abuse
Regulation (as it forms part of UK law pursuant to the European
Union (Withdrawal) Act 2018.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Andreas Rummelt
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Non-Executive Director
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the AstraZeneca PLC American Depositary
financial instrument, Shares
type of instrument
Identification code CUSIP: 046353108
---------------------------- -------------------------------------
b) Nature of the transaction Sale of AstraZeneca PLC American
Depositary Shares
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
US$65.23 15,170
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 5 May 2022
---------------------------- -------------------------------------
f) Place of the transaction XNAS
---------------------------- -------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUNARRUNUVRAR
(END) Dow Jones Newswires
May 06, 2022 11:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024